HCV: Written in our DNA

Self/Nonself - Immune Recognition and Signaling

Volumn 2, Issue 2, 2011, Pages 108-113

  Kanduc, Darja ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Genomic analysis; HCV immune recognition; Proteomic analysis; Self nonself; Unique HCV pentapeptides; Viral eukaryogenesis; Virus host relationship

Indexed keywords

ANTIVIRUS AGENT; DNA VACCINE; PEPTIDE; PROTEOME; VIRUS DNA; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN GENOME; IMMUNOGENICITY; IMMUNOTHERAPY; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; PROTEOMICS;

EID: 83155190464     PISSN: 19382030     EISSN: 19382049     Source Type: Journal    
DOI: 10.4161/self.2.2.15795     Document Type: Article

References (46)

1. Klein J. Self-nonself discrimination, histoincompatibil-ity and the concept of immunology. Immunogenetics 1999; 50:116-23.
2. Tauber AI. Metchnikoff and the phagocytosis theory. Nat Rev Mol Cell Biol 2003; 4:897-901.
3. Tauber AI, Podolsky SH. Frank Macfarlane Burnet and the immune self. J Hist Biol 1994; 27:531-73.
4. Pradeu T, Carosella ED. On the definition of a criterion of immunogenicity. Proc Natl Acad Sci USA 2006; 103:17858-61.
5. Janeway CA The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 1992; 13:11-6.
6. Oldstone MB. Anatomy of viral persistence. PLoS Pathog 2009; 5:1000523.
7. Sloots T P, Whiley DM, Lambert SB, Nissen MD. Emerging respiratory agents: new viruses for old diseases? J Clin Virol 2008; 42:233-43.
8. O'Donnell LA, Rall G F. Blue moon neurovirology: the merits of studying rare CNS diseases of viral origin. J Neuroimmune Pharmacol 2010; 5:443-55.
9. Sauter P, Hober D. Mechanisms and results of the antibody-dependent enhancement of viral infections and role in the pathogenesis of coxsackievirus B-induced diseases. Microbes Infect 2009; 11:443-51.
10. Kanduc D. "Self-nonself" peptides in the design of vaccines. Curr Pharm Des 2009; 15:3283-9.
11. Kanduc D. Epitopic peptides with low similarity to the host proteome: towards biological therapies without side effects. Expert Opin Biol Ther 2009; 9:45-53.
12. Kanduc D, Stufano A, Lucchese G, Kusalik A. Massive peptide sharing between viral and human proteomes. Peptides 2008; 29:1755-66.
13. Kusalik A, Bickis M, Lewis C, Li Y, Lucchese G, Marincola FM, et al. Widespread and ample peptide overlapping between HCV and Homo sapiens pro-teomes. Peptides 2007; 28:1260-7.
14. Kanduc D. Quantifying the possible cross-reactivity risk of an HPV16 vaccine. J Exp Ther Oncol 2009; 8:65-76.
15. Kanduc D. Penta- and hexapeptide sharing between HPV16 and Homo sapiens proteomes. Int J Med Med Sci 2009; 1:383-7.
16. Lucchese G, Stufano A, Kanduc D. Proteome-guided search for influenza A B-cell epitopes. FEMS Immunol Med Microbiol 2009; 57:88-92.
17. Kanduc D. Describing the hexapeptide identity platform between the influenza A H5N1 and Homo sapiens proteomes. Biologics 2010; 4:245-61.
18. Ricco R, Kanduc D. Hepatitis B virus and Homo sapiens proteome-wide analysis: A profusion of viral peptide overlaps in neuron-specific human proteins. Biologics 2010; 4:75-81.
19. Lucchese G, Stufano A, Kanduc D. Searching for an effective, safe and universal anti-HIV vaccine: finding the answer in just one short peptide. Self Nonself 2011; 1:49-54.
20. Lucchese G, Stufano A, Calabrò M, Kanduc D. Charting the peptide crossreactome between HIV-1 and the human proteome. Front Biosci 2011; 3:1385-400.
21. Landsteiner K, van der Scheer J. On the serological specificity of peptides. III. J Exp Med 1939; 69:705-19.
22. Reddehase MJ, Rothbard JB, Koszinowski UH. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature 1989; 337:651-3.
23. Papadouli I, Sakarellos C, Tzartos SJ. High-resolution epitope mapping and fine antigenic characterization of the main immunogenic region of the acetylcholine receptor: Improving the binding activity of synthetic analogues of the region. Eur J Biochem 1993; 211:227-34.
24. Endo M, Nunomura W, Takakuwa Y, Hatakeyama M, Higashi T. A novel epitope (pentapeptide) in the human hemoglobin beta chain. Hemoglobin 1998; 22:321-31.
25. Tiwari R, Geliebter J, Lucchese A, Mittelman A, Kanduc D. Computational peptide dissection of Melan-a/MART-1 oncoprotein antigenicity. Peptides 2004; 25:1865-71.
26. Zeng W, Pagnon J, Jackson DC. The C-terminal pen-tapeptide of LHRH is a dominant B cell epitope with antigenic and biological function. Mol Immunol 2007; 44:3724-31.
27. Stufano A, Capone G, Pesetti B, Polimeno L, Kanduc D. Clustering of rare peptide segments in the HCV immunome. Self/Nonself 2010; 1:154-62.
28. Stufano A, Kanduc D. Proteome-based epitopic peptide scanning along PSA. Exp Mol Pathol 2009; 86:36-40.
29. Lucchese G, Stufano A, Kanduc D. Proposing low similarity peptide vaccines against Mycobacterium tuberculosis. J Biomed Biotechnol 2010; 832341.
30. Lucchese G, Stufano A, Trost B, Kusalik A, Kanduc D. Peptidology: short amino acid modules in cell biology and immunology. Amino Acids 2007; 33:703-7.
31. Kanduc D. The self/nonself issue: A confrontation between proteomes. Self Nonself 2010; 1:255-8.
32. Wu CH, Yeh LS, Huang H, Arminski L, Castro-Alvear J, Chen Y, et al. The Protein Information Resource. Nucleic Acids Res 2003; 31:345-7.
33. Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991; 88:2451-5.
34. Altschul S F, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25:3389-402.
35. Nakamuta M, Fujino T, Yada R, Aoyagi Y, Yasutake K, Kohjima M, et al. Expression profiles of genes associated with viral entry in HCV-infected human liver. J Med Virol 2011; 83:921-7.
36. Polyak SJ, Klein KC, Shoji I, Miyamura T, Lingappa JR. Assemble and interact: pleiotropic functions of the HCV core protein. In: Tan SL, Editor. Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk (UK): Horizon Bioscience 2006.
37. Ke PY, Chen SS. Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. J Clin Invest 2011; 121:37-56.
38. Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland S F, Isogawa M, et al. A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2008; 105:3088-93.
39. Bell PJ. The viral eukaryogenesis hypothesis: a key role for viruses in the emergence of eukaryotes from a pro-karyotic world environment. Ann NY Acad Sci 2009; 1178:91-105.
40. Koonin EV, Senkevich TG, Dolja VV. The ancient Virus World and evolution of cells. Biol Direct 2006; 1:29.
41. Lechmann M, Liang TJ. Vaccine development for hepatitis C. Semin Liver Dis 2000; 20:211-26.
42. Alvarez-Lajonchere L, Dueñas-Carrera S. Advances in DNA immunization against hepatitis C virus infection. Hum Vaccin 2009; 5:568-71.
43. Baumert T F, Vergalla J, Satoi J, Thomson M, Lechmann M, Herion D, et al. Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology 1999; 117:1397-407.
44. Cai W, Su L, Liao Q, Ye L, Wu Y, Wu Z, et al. Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast. Antiviral Res 2010; 88:80-5.
45. Vajdy M, Selby M, Medina-Selby A, Coit D, Hall J, Tandeske L, et al. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J Gen Virol 2006; 87:2253-62.
46. Bhopale GM, Nanda RK. Prospects for hepatitis C vaccine. Acta Virol 2004; 48:215-21.